Spain Pharmaceuticals and Healthcare Report Q1 2010

Executive Summary ..................................5
SWOT Analysis..........................................6
Spain: Pharmaceutical And Healthcare Industry SWOT ................................ 6
Spain Political SWOT.................................. 7
Spain Economic SWOT................................ 7
Pharmaceutical Business Environment Ratings .......................................8
Table: Western Europe Pharmaceutical Business Environment Ratings for Q110............................................. 8
Limits to Potential Returns .......................... 8
Risks to Realisation of Potential Returns ........................................................ 9
Spain – Market Summary........................11
Regulatory Regime..................................13
Recent Regulatory Developments .............. 14
Intellectual Property Issues ....................... 14
Intellectual Property Deficiencies.............. 15
Parallel Trade............................................ 15
Pricing and Reimbursement Issues ............ 16
Table: Timeline – Spain’s Pharmaceutical Pricing Reforms ......................... 17
Reference Pricing System .......................... 19
OTC Market............................................... 20
Recent Pricing and Reimbursement Developments....................................... 21
Industry Developments...........................23
Epidemiology............................................. 23
Table: Spain - Mortality by Select Causes .................................................... 23
Healthcare Sector ...................................... 24
Table: SNS Debt 2007................................ 25
Medical Tourism........................................ 26
Pharmaceutical Retail ............................... 27
Research and Development........................ 28
Clinical Trials............................................ 29
Medical Devices......................................... 30
Industry Forecast Scenario .....................32
Overall Market Forecast............................ 32
Key Growth Factors – Industry.................. 33
Key Growth Factors – Macroeconomic ........................................................ 34
Spain – GDP Contribution To Growth, 2007-2014....................................... 35
Table: Spain – Economic Activity, 2006-2014 .............................................. 37
Table: Spain Long-Term Macroeconomic Forecasts, 2012-2019 .................. 37
Prescription Drug Market Forecast........... 38
Patented Product Market Forecast ............ 41
Generic Drug Market Forecast.................. 42
OTC Market Forecast................................ 44
Medical Device Market Forecast............... 46
Pharmaceutical Trade Forecast ................ 47
Other Healthcare Data .............................. 49
Key Risks to BMI Forecasts ....................... 50
Competitive Landscape..........................51
Pharmaceutical Sector............................... 51
Foreign Industry ........................................ 51
Indigenous Sector ...................................... 53
Generic Drug Sector.................................. 54
Biotechnology Sector ................................. 55
Table: Firms Active In Nanofarma Consortium............................................ 57
Company Profiles....................................59
Leading Multinational Manufacturers ............ 59
GlaxoSmithKline (GSK)............................. 59
Pfizer ......................................................... 60
Novartis ..................................................... 62
Sanofi-Aventis............................................ 64
Merck & Co ............................................... 66
Indigenous Manufacturers .............................. 67
Almirall...................................................... 67
Dr Esteve ................................................... 70
Country Snapshot: Spain Demographic Data ..........................................72
Section 1: Population................................. 72
Table: Demographic Indicators, 2005-2030................................................. 72
Table: Rural/Urban Breakdown, 2005-2030 ................................................ 73
Section 2: Education and Healthcare ........ 73
Table: Education, 2002-2005 .................... 73
Table: Vital Statistics, 2005-2030.............. 73
Section 3: Labour Market and Spending Power............................................ 74
Table: Employment Indicators, 2001-2006................................................... 74
Table: Consumer Expenditure, 2000-2012 (US$) ......................................... 74
Table: Average Annual Manufacturing Wages, 2000-2012 .......................... 75
BMI Methodology ....................................76
How We Generate Our Pharmaceutical Industry Forecasts .............................. 76
Pharmaceutical Business Environment Ratings Methodology ........................... 77
Ratings Overview....................................... 77
Table: Pharmaceutical Business Environment Indicators ............................ 78
Weighting................................................... 79
Table: Weighting Of Components.............. 79
Sources ........ 79
Forecast Tables .......................................80